First results of the Russian multicenter epidemiology project on the malignant gliomas

Abstract

There is no official data on malignant glioma morbidity in Russian Federation. The data absence became the main reason for Russianmulticenter project conduction to research malignant gliomas’ epidemiology. The epidemiology data and glioblastoma treatment approac-hes are presented in the article. Significant variability of 1st line treatment choice both for radiotherapy and combined therapy was confir-med. The current treatment standard (chemoradiotherapy + temozolomid) is received only by one of every four patients with new diagno-sed glioblastoma. Less than half of patients receive 2nd line therapy, which apparently influences on patient’s life duration. More than thirdof patients with recurrent glioblastoma received bevacizumab.

Keywords

• glioblastoma multiforme
• brain tumor
• chemoradiotherapy
• target therapy
• antiangiogenic therapy
• bevacizumab